Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Strategic Vision and Pipeline Advancement
CYTK logo

Cytokinetics Aficamten NDA Advances with $1.22B Cash Boost

CYTK10-KFiling Date: 2/27/2025
Cytokinetics, Incorporated
Description

What this story covers

Cytokinetics advances aficamten toward 2025 FDA approval for oHCM, backed by Phase 3 wins and $1.22B cash. Vision 2030 targets two approvals, global reach for 100,000 patients. Pipeline includes omecamtiv mecarbil and early assets; risks include regulatory delays and competition.

Story snapshot

CompanyCytokinetics, Incorporated
TickerCYTK
VariantStandard detailed
Duration13:06
Filing type10-K
PeriodAnnual 2024
IndustryHealthcare & Pharmaceuticals
Accession0000950170-25-029206

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in